Hemoglobin
Osteomyelitis in Sickle Cell Anemia
search
Osteomyelitis in Sickle Cell Anemia
, Osteomyelitis in Thalassemia, Osteomyelitis in Hemoglobinopathy
See Also
Osteomyelitis
Sickle Cell Anemia
Transient Red Cell Aplasia
Acute Chest Syndrome
Acute Vaso-Occlusive Episode in Sickle Cell Anemia
Aplastic Crisis in Sickle Cell Anemia
Cerebrovascular Accident in Sickle Cell Anemia
Dactylitis in Sickle Cell Anemia
(
Hand Foot Syndrome in Sickle Cell Anemia
)
Hematuria in Sickle Cell Anemia
Priapism in Sickle Cell Anemia
Pulmonary Hypertension in Sickle Cell Anemia
Septic Arthritis in Sickle Cell Anemia
Sickle Cell Anemia Related Pulmonary Hypertension
Sickle Cell Anemia with Splenic Sequestration
Pathophysiology
Infection of infarcted bone
Most common
Osteomyelitis
sites (due to highly vascular
Bone Marrow
)
Long bones (multiple sites in same bone may be involved)
Spine
Sternum
Causes
Bone infarction
Bone infarction is far more common than
Osteomyelitis
Infections
See See
Osteomyelitis
Staphylococcal Aureus (<25% of cases)
Salmonella
SCA patients are susceptible to this encapsulated organism due to
Asplenia
Most common organism in
Sickle Cell Anemia
Osteomyelitis
Other
Gram Negative Bacteria
may also occur
Signs
Fever
Fever
duration directly correlates with likelihood of
Osteomyelitis
(risk increases 80% each day of fever)
Extremity swelling
Osteomyelitis
likelihood increases 8.4 fold
Bone pain
Osteomyelitis
likelihood increases 20% each day of pain
Diagnosis
Bone Culture
Labs
Blood Culture
s
Test Sensitivity
: 30 to 76%
Imaging
See
Osteomyelitis
Interpretation may be difficult in
Sickle Cell Anemia
as bone infarcts may appear similar to
Osteomyelitis
Management
See
Osteomyelitis
Bone infarctions are typically self limited (in contrast, of course, to
Osteomyelitis
)
Antibiotic
s are similar to those used in other
Osteomyelitis
with added
Salmonella
and
Gram Negative
coverage
Total
Antibiotic
course: 6 to 8 weeks
Initial IV:
Vancomycin
AND (
Ciprofloxacin
or
Ceftriaxone
)
Later: May transition to Oral fluoroquinonoles (
Ciprofloxacin
,
Levofloxacin
) for susceptible
Gram Negative
causes
References
Dwyer, Kleinmann, Goswami and Lopez (2025) Crit Dec Emerg Med 39(1): 26-35
Lowe and Wang (2018) Crit Dec Emerg Med 32(11): 17-25
Welsh and Welsh (2016) Crit Dec Emerg Med 30(11): 15-23
Type your search phrase here